Bayer Intellectual Property Gmbh

Bayer Schering Pharma Ag

Bayer Aktiengesellschaft

Bayer Pharma Aktiengesellschaft

Peter Ellinghaus

Michael Härter

Hilmar Bischoff

Hartmut Beck

Susanne Greschat

Joachim Schuhmacher

Peter Kolkhof

Gunter Schmidt

Nils Griebenow

Manoj Patel

Axel Kretschmer

Karl-Heinz Thierauch

Anja Buchmüller

Helmut Haning

Barbara Albrecht-Küpper

Stefan Golz

Ulf Brüggemeier

Timo Flessner

Holger Hess-Stumpp

Verena V&ouml;hringer

Andreas Geerts

Michael Woltering

Christiane Faeste

Martina Klein

Stephen James Boyer

Sonja Steppan

Ellalahewage Sathyajith Kumarasinghe

Philip Wickens

Holger Summer

Kerstin Berhörster

Patrick Paulus

Martin Raabe

Hendrik Milting

Michael Seewald

Donatella D'Urso

Ajay Kumar Bhargava

Susanne Greschat-Schade

Donatella D'urso

Kerstin Berhoerster

This invention relates to novel heteroaryl substituted pyrazole compounds, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for treating hyper-proliferative and/or angiogenesis disorders, as a sole agent or in combination with other active ingredients or therapeutic measures.

Heteroaryl substituted pyrazole derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis

The present application relates to novel substituted 1-[3-(heterocyclyl)benzyl]-1H-pyrazole derivatives, to processes for preparation thereof, to use thereof for treatment and/or prevention of diseases and to use thereof for production of medicaments for treatment and/or prevention of diseases, more particularly for treatment and/or prevention of hyperproliferative and angiogenic diseases and those diseases which arise from metabolic adaptation to hypoxic states. Such treatments can be effected in the form of monotherapy or else in combination with other medicaments or further therapeutic measures.

Substituted heterocyclylbenzylpyrazoles and use thereof

The invention provides LTBP2, which is associated with cardiovascular diseases, hematological diseases, neurological diseases, cancer, endocrinological diseases, and urological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, hematological diseases, neurological diseases, cancer, endocrinological diseases, and urological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of LTBP2 as well as pharmaceutical compositions comprising such compounds. The invention also provides LTBP2 as a biomarker for diseases such as cardiovascular diseases, hematological diseases, neurological diseases, cancer, endocrinological diseases, and urological diseases.

LTBP2 as a biomarker and diagnostic target

The present application relates to novel tetrahydrobenzo[d]azepin-2-one derivatives, processes for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for producing medicaments for the treatment and/or prophylaxis of diseases, preferably for the treatment and/or prevention of cardiovascular disorders, especially of dyslipidaemias, arteriosclerosis, restenosis and ischaemias.

Tetrahydrobenzo[d]azepin-2-one derivatives and the use thereof for treating cardiovascular diseases

Diphenyl derivatives

Growing community of inventors

Melle, Germany

Peter Ellinghaus